Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Change in Cash (2018 - 2025)

Inmune Bio's Change in Cash history spans 8 years, with the latest figure at -$5.6 million for Q3 2025.

  • For Q3 2025, Change in Cash fell 327.14% year-over-year to -$5.6 million; the TTM value through Sep 2025 reached -$5.8 million, up 29.57%, while the annual FY2024 figure was -$14.9 million, 8.46% up from the prior year.
  • Change in Cash for Q3 2025 was -$5.6 million at Inmune Bio, down from $14.0 million in the prior quarter.
  • Across five years, Change in Cash topped out at $45.0 million in Q3 2021 and bottomed at -$12.6 million in Q4 2024.
  • The 5-year median for Change in Cash is -$5.3 million (2022), against an average of $303526.3.
  • The largest annual shift saw Change in Cash skyrocketed 2294.65% in 2021 before it crashed 756.17% in 2024.
  • A 5-year view of Change in Cash shows it stood at -$9.7 million in 2021, then surged by 45.64% to -$5.3 million in 2022, then dropped by 13.58% to -$6.0 million in 2023, then crashed by 111.74% to -$12.6 million in 2024, then soared by 55.34% to -$5.6 million in 2025.
  • Per Business Quant, the three most recent readings for INMB's Change in Cash are -$5.6 million (Q3 2025), $14.0 million (Q2 2025), and -$1.6 million (Q1 2025).